133 related articles for article (PubMed ID: 37114985)
1. Optimal biological dose selection in dose-finding trials with model-assisted designs based on efficacy and toxicity: a simulation study.
Yamaguchi Y; Takeda K; Yoshida S; Maruo K
J Biopharm Stat; 2024 May; 34(3):379-393. PubMed ID: 37114985
[TBL] [Abstract][Full Text] [Related]
2. A utility-based Bayesian optimal interval (U-BOIN) phase I/II design to identify the optimal biological dose for targeted and immune therapies.
Zhou Y; Lee JJ; Yuan Y
Stat Med; 2019 Dec; 38(28):5299-5316. PubMed ID: 31621952
[TBL] [Abstract][Full Text] [Related]
3. TITE-BOIN12: A Bayesian phase I/II trial design to find the optimal biological dose with late-onset toxicity and efficacy.
Zhou Y; Lin R; Lee JJ; Li D; Wang L; Li R; Yuan Y
Stat Med; 2022 May; 41(11):1918-1931. PubMed ID: 35098585
[TBL] [Abstract][Full Text] [Related]
4. TEPI-2 and UBI: designs for optimal immuno-oncology and cell therapy dose finding with toxicity and efficacy.
Li P; Liu R; Lin J; Ji Y
J Biopharm Stat; 2020 Nov; 30(6):979-992. PubMed ID: 32951518
[TBL] [Abstract][Full Text] [Related]
5. A comparative study of adaptive trial designs for dose optimization.
Zhang J; Chen X; Li B; Yan F
Pharm Stat; 2023; 22(5):797-814. PubMed ID: 37156731
[TBL] [Abstract][Full Text] [Related]
6. CFO: Calibration-free odds design for phase I/II clinical trials.
Jin H; Yin G
Stat Methods Med Res; 2022 Jun; 31(6):1051-1066. PubMed ID: 35238697
[TBL] [Abstract][Full Text] [Related]
7. Bayesian adaptive model selection design for optimal biological dose finding in phase I/II clinical trials.
Lin R; Yin G; Shi H
Biostatistics; 2023 Apr; 24(2):277-294. PubMed ID: 34296266
[TBL] [Abstract][Full Text] [Related]
8. A Bayesian adaptive Phase I-II clinical trial for evaluating efficacy and toxicity with delayed outcomes.
Koopmeiners JS; Modiano J
Clin Trials; 2014 Feb; 11(1):38-48. PubMed ID: 24082004
[TBL] [Abstract][Full Text] [Related]
9. A software tool for both the maximum tolerated dose and the optimal biological dose finding trials in early phase designs.
Li C; Sun H; Cheng C; Tang L; Pan H
Contemp Clin Trials Commun; 2022 Dec; 30():100990. PubMed ID: 36203850
[TBL] [Abstract][Full Text] [Related]
10. 2D (2 Dimensional) TEQR design for Determining the optimal Dose for safety and efficacy.
Ananthakrishnan R; Green S; Li D; LaValley M
Contemp Clin Trials Commun; 2019 Dec; 16():100461. PubMed ID: 31799471
[TBL] [Abstract][Full Text] [Related]
11. gBOIN-ET: The generalized Bayesian optimal interval design for optimal dose-finding accounting for ordinal graded efficacy and toxicity in early clinical trials.
Takeda K; Morita S; Taguri M
Biom J; 2022 Oct; 64(7):1178-1191. PubMed ID: 35561046
[TBL] [Abstract][Full Text] [Related]
12. Optimal biological dose: a systematic review in cancer phase I clinical trials.
Fraisse J; Dinart D; Tosi D; Bellera C; Mollevi C
BMC Cancer; 2021 Jan; 21(1):60. PubMed ID: 33441097
[TBL] [Abstract][Full Text] [Related]
13. BOIN-ET: Bayesian optimal interval design for dose finding based on both efficacy and toxicity outcomes.
Takeda K; Taguri M; Morita S
Pharm Stat; 2018 Jul; 17(4):383-395. PubMed ID: 29700965
[TBL] [Abstract][Full Text] [Related]
14. BOIN12: Bayesian Optimal Interval Phase I/II Trial Design for Utility-Based Dose Finding in Immunotherapy and Targeted Therapies.
Lin R; Zhou Y; Yan F; Li D; Yuan Y
JCO Precis Oncol; 2020; 4():. PubMed ID: 33283133
[TBL] [Abstract][Full Text] [Related]
15. Evaluating the performance of copula models in phase I-II clinical trials under model misspecification.
Cunanan K; Koopmeiners JS
BMC Med Res Methodol; 2014 Apr; 14():51. PubMed ID: 24731155
[TBL] [Abstract][Full Text] [Related]
16. Bayesian optimization design for dose-finding based on toxicity and efficacy outcomes in phase I/II clinical trials.
Takahashi A; Suzuki T
Pharm Stat; 2021 May; 20(3):422-439. PubMed ID: 33258282
[TBL] [Abstract][Full Text] [Related]
17. STEIN: A simple toxicity and efficacy interval design for seamless phase I/II clinical trials.
Lin R; Yin G
Stat Med; 2017 Nov; 36(26):4106-4120. PubMed ID: 28786138
[TBL] [Abstract][Full Text] [Related]
18. Sequential or combined designs for Phase I/II clinical trials? A simulation study.
Rossoni C; Bardet A; Geoerger B; Paoletti X
Clin Trials; 2019 Dec; 16(6):635-644. PubMed ID: 31538815
[TBL] [Abstract][Full Text] [Related]
19. TSNP: A two-stage nonparametric phase I/II clinical trial design for immunotherapy.
Han Y; Liu H; Cao S; Zhang C; Zang Y
Pharm Stat; 2021 Mar; 20(2):282-296. PubMed ID: 33025762
[TBL] [Abstract][Full Text] [Related]
20. uTPI: A utility-based toxicity probability interval design for phase I/II dose-finding trials.
Shi H; Cao J; Yuan Y; Lin R
Stat Med; 2021 May; 40(11):2626-2649. PubMed ID: 33650708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
